Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr. Sytkowsei on our team:
"We are pleased that Dr. Sytkowski will remain such an integral part of our Company," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "As one of the foremost scientists in the field of therapeutic protein research and particularly Erythropoietin, Dr. Sytkowski will bring to bear his considerable expertise on the development and the marketing of PT-401, our lead pharmaceutical product being developed for the treatment of anemia. We look forward to working with him on this project and any future endeavors."
Dr. Sytkowski is a physician and scientist with more than 25 years of clinical and research experience in the fields of oncology, hematology, cell and molecular biology, and protein biochemistry. He is an Associate Professor in the Department of Medicine at the Harvard Medical School and a member of the Division of Hematology and Oncology at BIDMC. He has authored a book on Erythropoietin entitled "Erythropoietin: Blood, Brain and Beyond" and has authored many scientific papers and several milestone patents covering Erythropoietin. Furthermore, he has served as an expert witness and advisor to leading pharmaceutical companies selling Erythropoietin products.
DNAPrint Genomics is already working with Dr. Sytkowski and BIDMC to develop a new, more potent and longer acting form of the drug Erythropoietin (EPO) for the treatment of anemia. Under the terms of that agreement, BIDMC has granted the Company an exclusive license to United States and foreign patents related to certain forms of EPO, including PT-401.
Ann
"We will assist Emory's scientific team to help them develop the necessary skills for running our rigorous testing, Quality Control and Quality Assurance protocols," said Dr. Matt Thomas, Senior Scientist and Manager of Laboratory Operations for DNAPrint Genomics. "Our test kits have performed nearly 45,000 tests on human DNA and we have spent significant time and effort to assure high standards in our testing. We are excited about applying our analysis to clinical trial patients in order to better understand diseases and to develop 'theranostic' test/drug combinations that will improve efficacy and reduce side effects."
Ann
DNAP & Emory Univ. Center:
http://www.marketwire.com/mw/release_html_b1?release_id=154684
Ann
Spanish firm & DNAP alliance:
http://tampabay.bizjournals.com/tampabay/stories/2006/08/21/daily15.html
Ann
Congratulations Grandpa Froggy!
Take care,
Ann
ebo:
If she's as sharp as you say, I hope she will keep the site current and updated in a timely manner.
Take care,
Ann
Very cute TLV,
Ann (Mother of Three) - lol
Ok, Chris & Bag!
A nice weekend to all,
Ann
Bag:
I have already received a reply this a.m.:
Thank you for your comments. We are planning on reviewing the website during the middle to end of September and will make it more appealing to the eye.
Again, thanks for taking the time to let us know!
Karen Surplus
DNAPrint Genomics, Inc.
941-366-3400 X227
727-709-1408 cell
813-435-2230 e-fax
Ann
(Current) Human Resources Job Availability:
Lab Technician
DNAPrint Genomics, Inc., is currently accepting applications for a laboratory technician position available for a B.S. or M.S.-level scientist who has previous experience working in either an academic or forensics laboratory. This person should be well versed in not only classical genetics but modern genome based techniques. Technician will operate capillary electrophoresis and automated Beckman equipment (multimek liquid handling system, Ultra High Throughput instruments). This person will be involved in the production of customer results as well as research and development work on a variety of projects. Additionally, general lab maintenance and equipment calibration will form a portion of this position. An applicant should be capable of working within the confines of pre-defined standard operating procedures, and of developing new ones as the needs of the company change. Experience and familiarity with DNA extraction, PCR, sequencing, fragment analysis and other molecular biology techniques is required for this position.
Salary is commensurate with experience. Benefits include health insurance, 401K plan, annual leave. Job is located at the corporate headquarters in Sarasota, Florida. No phone calls. Please send resume and cover letter by fax, e-mail, or U.S. mail to:
Human Resources
DNAPrint Genomics, Inc.
900 Cocoanut Avenue
Sarasota FL 34236
FAX: 941-955-9770
lfranklin@dnaprint.com
Ann
I also sent an additional e-mail to Webmasters:
"I believe DNAP should seek to invest additional funds into designing a more "dynamically visual web site." This has been my opinion & observation from the onset of my early investment in DNAP...and in my professional opinion... PRESENTATION is of extreme relevance to sales of a company's level of marketable corporate products.
Ann
Sent this e-mail to DNAP webmasters:
Please consider "waking up" the DNAPrint web site by more alert & active color insertions, animations, video & audio displays.
In my opinion, the DNAP website currently lacks the projections & lackluster of a top-notch company labeled as an "A-1 winner in it's field!"
For what it's worth, I used to work for a top 10 Ad Agency in NY.
And to boot, a "very long-time" avid investor,
Ann
Wall St. Reporter Interview available til Nov. '06:
Mr. Gabriel also gave insights into the revenue potential for DNA research and an update on the development of compounds to treat various diseases. He elaborated on the revenue potential for the Company's relationships with Biofrontera of Germany, in which the company has a significant ownership stake, as well as the continuing relationship with Harvard University's Beth Israel Deaconess Hospital and the new relationship with Emory University's Center for Medical Genomics.
The interview is available for streaming by going to http://www.wallstreetreporter.com/profile.php?id=19412. Free registration is required to enter the site. The interview will be available in the site's archive until November 15, 2006.
ANN
News Release - "Correction on DNAP's Press Release"
http://money.aol.com/news/articles/_a/correction-dnaprint-genomics-inc/n20060824073509990024
Ann
DNAP, DOCRO & Vascular Complications:
http://www.marketwire.com/mw/release_html_b1?release_id=109692
Ann
Pre-Clinical Development of Anemia Drug:
http://press.arrivenet.com/health/article.php/796700.html
Ann
DNAP & Emory University Center:
http://www.genengnews.com/news/bnitem.aspx?name=4803854
Ann
Chris:
Right on.
Take care,
Ann
DNAP reminder:
"Kenna, based in West Chester, Pa., was a privately held company. The firm builds computer models that mimic complex biological systems.
Kenna's technologies are expected to lead to shorter and less expensive drug development times, Dr. Hector Gomez, chairman and chief medical officer of DNA Print genomics, said in a release.
Kenna's technologies "represent a powerful tool in our company's search to develop programs for personalized medicine and test/drug combinations targeting a specific group of patients," he said.
Ann
Looks like an old news release, but as an old-time investor, don't even remember it way back when.
Ann
Certainly don't remember this news:
http://www.altura2000.com/press_DNA.html
Ann
And wasn't this good news when we received it?
http://news.biocompare.com/newsstory.asp?id=104695
Ann
Biodefense Council Decisions
The following members of the committee support these decisions: Carolyn Ruth Bertozzi (University of California, Berkeley; Howard Hughes Medical Institute; University of California, San Francisco, Lawrence Berkeley National Laboratory); Peter Charles Doherty (St. Jude Children's Research Hospital and The University of Melbourne); Tony N. Frudakis (DNAPrint genomics, Inc.); David Jonathan Harris (Biodefense Council), William Matthew Jaunich (Biodefense Council); Jay Frederick Krehbiel (Audax Private Equity); Elaine Rene Mardis (Washington University); Christina Dawn Smolke (California Institute of Technology).
Ann
Tony Frudakis on this Bio Council list:
http://sev.prnewswire.com/biotechnology/20051106/NYSU03107112005-1.html
Ann
usmc:
DNAP on PMC Membership List - that Stckhldr just posted - take another look:
http://www.personalizedmedicinecoalition.org/about/pmc_members.php
Ann
usmc:
"try saying something good for once"
"Something Good" - There, I'll say it for him. You know HE never will - lol
Ann
Foo...er sorry, Fru:
" I am only here, like many others, to find some rational answers as to why this is still such a poor and deteriorating investment."
Now we see why you're here - but, I can find better ways to spend my money - lol
Ann
NAP wire.com/mw/release_html_b1?release_id=151639
Ugraded Witness sales:
http://www.marketwire.com/mw/release_html_b1?release_id=152528
Ann
"Very Impressiv" Emory School of Medicine:
http://www.med.emory.edu/index.cfm
Ann
This is the Emory School of Medicine:
http://www.med.emory.edu/index.cfm
Ann
A look at this announcement via a pr:
http://money.aol.com/news/articles/_a/dnaprint-genomics-and-emory-university/n20060817075009990043
Ann
Have a great one, usmc
Ann
usmc:
Agreed re: the politics. Tox needs to keep the politics on a different board. Glad to have you aboard our board - lol
Ann
K-BioPharma:
http://www.kbibiopharma.com/
Ann